Elimelech Rosner - Healthequity Ex CTO

2HE Stock  EUR 99.00  2.00  2.06%   

Insider

Elimelech Rosner is Ex CTO of Healthequity
Age 66
Phone801 727 1000
Webhttps://www.healthequity.com

Elimelech Rosner Latest Insider Activity

Tracking and analyzing the buying and selling activities of Elimelech Rosner against Healthequity stock is an integral part of due diligence when investing in Healthequity. Elimelech Rosner insider activity provides valuable insight into whether Healthequity is net buyers or sellers over its current business cycle. Note, Healthequity insiders must abide by specific rules, including filing SEC forms every time they buy or sell Healthequity'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Healthequity Management Efficiency

Healthequity's management efficiency ratios could be used to measure how well Healthequity manages its routine affairs as well as how well it operates its assets and liabilities.
Healthequity has accumulated 922.08 M in total debt with debt to equity ratio (D/E) of 7.5, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Healthequity has a current ratio of 15.29, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Healthequity until it has trouble settling it off, either with new capital or with free cash flow. So, Healthequity's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Healthequity sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Healthequity to invest in growth at high rates of return. When we think about Healthequity's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

David BullockOrigin Agritech
49
Seth FrankEvolent Health
N/A
Allison MillerNMI Holdings
N/A
Amir KhoshniyatiIdentiv
N/A
Patric ErlandssonSIVERS SEMICONDUCTORS AB
51
Ash RajendraSuperior Plus Corp
N/A
Caroline SchlienkampTalanx AG
49
Robert GreenSIVERS SEMICONDUCTORS AB
60
MAAA FSAEvolent Health
50
Bjorn NorrbomSIVERS SEMICONDUCTORS AB
72
Jan WickeTalanx AG
55
Geoffery MerszeiOrigin Agritech
68
Mike TaylorIdentiv
N/A
CCLP CMASuperior Plus Corp
62
JeanJacques HenchozTalanx AG
59
Wilm LangenbachTalanx AG
52
Torsten LeueTalanx AG
57
James DevensSuperior Plus Corp
N/A
Erik FallstromSIVERS SEMICONDUCTORS AB
56
Steven HumphreysIdentiv
62
Christopher LohmannTalanx AG
55
HealthEquity, Inc. provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. HealthEquity, Inc. was founded in 2002 and is headquartered in Draper, Utah. HealthEquity operates under Health Information Services classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1141 people. Healthequity (2HE) is traded on Frankfurt Exchange in Germany and employs 3,688 people.

Management Performance

Healthequity Leadership Team

Elected by the shareholders, the Healthequity's board of directors comprises two types of representatives: Healthequity inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Healthequity. The board's role is to monitor Healthequity's management team and ensure that shareholders' interests are well served. Healthequity's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Healthequity's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jon Kessler, President CEO, Director
Darcy Mott, CFO, Executive Vice President
Delano Ladd, Executive Vice President General Counsel and Corporate Secretary
Brad Bennion, Sr Devel
Tyson Murdock, Ex CFO
Elimelech Rosner, Ex CTO
Tia Padia, VP Marketing
Richard Putnam, IR Contact Officer
Steve Lindsay, Ex Management
Larry Trittschuh, Executive Vice President Chief Security Officer

Healthequity Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Healthequity a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Healthequity Stock

When determining whether Healthequity offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Healthequity's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Healthequity Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Healthequity Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Healthequity. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Healthequity Stock please use our How to Invest in Healthequity guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Please note, there is a significant difference between Healthequity's value and its price as these two are different measures arrived at by different means. Investors typically determine if Healthequity is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Healthequity's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.